Home  >  Products  >  BCL11A (B-cell CLL/lymphoma 11A (zinc finger protein)) Blocking Peptide (the C terminal of BCL11A)(100ug)
BCL11A (B-cell CLL/lymphoma 11A (zinc finger protein)) Blocking Peptide (the C terminal of BCL11A)(100ug)

BCL11A (B-cell CLL/lymphoma 11A (zinc finger protein)) Blocking Peptide (the C terminal of BCL11A)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-BCL11A Antibody (ARP39569_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP39569
Size: 100ug
Weight: 91kDa
Gene: 53335
Format: Lyophilized powder
Target: BCL11A is a C2H2 type zinc-finger protein by its similarity to the mouse Bcl11a/Evi9 protein. The corresponding mouse gene is a common site of retroviral integration in myeloid leukemia, and may function as a leukemia disease gene, in part, through its interaction with BCL6. During hematopoietic cell differentiation, this gene is down-regulated. It is possibly involved in lymphoma pathogenesis since translocations associated with B-cell malignancies also deregulates its expression.
Alternative names: BCL11A-L; BCL11A-S; BCL11A-XL; CTIP1; EVI9; FLJ10173; FLJ34997; HBFQTL5; KIAA1809; ZNF856
See Full Product Listings >